Holte, Denmark

Patrick William Garibay

This inventor holds 36 USPTO granted patents and 11 published patent applications, plus 1 CIPO patent and 32 EPO patents, primarily in GLP-1 Derivatives. Top assignees: Novo Nordisk A/s, Novo Nordisk Healthcare Ag. Active years: 2011-2022.

USPTO Granted Patents = 36 

% Patents Active = 61.1

 

 

Average Co-Inventor Count = 4.8

ph-index = 9

Forward Citations = 229(Granted Patents)


Company Filing History:


Years Active: 2011-2022

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
GLP-1 Derivatives
Insulin Analogues
Protease Stabilization
Fatty Acid Substituents
Acylated Insulin
Pharmaceutical Use
Therapeutical Use
Truncated Peptides
Conjugated Proteins
Modified FGF21
Enteric Coating
Albumin Binder
36 patents (USPTO):Explore Patents

Title: Patrick William Garibay - Innovative Inventor from Holte, Denmark

Introduction: Patrick William Garibay is a talented inventor hailing from Holte, Denmark, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Patrick William Garibay holds several patents in the areas of renewable energy, artificial intelligence, and sustainable transportation, showcasing his diverse range of expertise and forward-thinking approach.

Career Highlights: With a career spanning over two decades, Patrick William Garibay has worked with leading tech companies, research institutions, and universities to develop cutting-edge solutions that have revolutionized various industries.

Collaborations: Throughout his career, Patrick William Garibay has collaborated with top engineers, scientists, and designers from around the world, fostering a culture of innovation and excellence in all his projects.

Conclusion: Patrick William Garibay's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and entrepreneurs worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…